Accordingly, molecular profiling of CCA tumours has become increasingly significant over the past few years due to the identification of potentially druggable molecular alterations, such as mutations in IDH1/2 and FGFR2 fusions. This evidence concerns the gene FGFR2 and cholangiocarcinoma.